Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
This randomised, double-blind, placebo-controlled trial (n=26) aims to investigate the safety and efficacy of ketamine and riluzole in patients with treatment-resistant major depressive disorder. Additionally, the study will assess whether lamotrigine can mitigate ketamine-associated side effects.
Details
Randomised, double‑blind, factorial study (n=26) evaluating whether lamotrigine pre‑treatment (300 mg, 2 h prior) modifies acute response to a single IV subanesthetic racemic ketamine infusion in treatment‑resistant major depressive disorder; responders entered a 4‑week randomized continuation to riluzole 100 mg/day or placebo.
Primary outcomes include safety and efficacy measures; design includes a pre‑treatment (lamotrigine vs placebo) and a continuation phase (riluzole vs matching placebo) in ketamine responders.